Advance Nanotech Senior Executives to Speak at NSTI Nanotech 2006 Conference
May 08, 2006 12:26 PM US Eastern Timezone
Advance Nanotech is dedicated to the successful commercialization of disruptive nanotechnologies to produce nano-enabled products.BOSTON--(BUSINESS WIRE)--May 8, 2006--Advance Nanotech, Inc., (OTCBB:AVNA), the premier provider of financing and support services to expedite the commercialization of nanotechnology discoveries, today announced that several members of its senior executive team will speak at the Nano Science and Technology Institute's (NSTI) Nanotech 2006 Symposium in Boston Mass., May 8 - 9 at the Hynes Convention Center, 900 Boylston Street. Advance Nanotech is a Gold Sponsor of Nanotech 2006, which is expected to attract more than 4,000 participants from 50 countries.
-- Advance Nanotech CEO Magnus Gittins will deliver a speech entitled Nanotechnology: Creating Real Value. Mr. Gittins' discussion will focus on the future of nanotechnology, and the need for a new investment model to best meet the challenges and opportunities of the sector. Mr. Gittins will present on Monday, May 8 at 10:30 am in room 207 at the Hynes Convention Center.
-- Advance Nanotech Senior Vice President, Electronics, Peter Gammel will deliver a presentation on Securing the Homeland: Cheaper, Faster & Better. Dr. Gammel's presentation will take place on May 8 from 4:50 pm to 5:15 pm in room 208 at the Hynes Convention Center.
-- Owlstone Nanotech CEO Brett Bader will deliver a presentation on the future of chemical detection technology. Mr. Bader will present on May 8 from 5:00 pm to 5:30 pm in room 303 at the Hynes Convention Center.
-- Advance Nanotech Senior Vice President, Bio/Pharma, Michael Helmus will be participating in two presentations at NSTI;
-- Show Me the Value: What Investors and Partners Look For (And Avoid) When Investing In Technology: May 10, from 2:10 pm to 2:30 pm in room 207 at the Hynes Convention Center
-- Bio Materials and Tissues: May 11, from 10:30 pm to 11:50 pm in room 104 at the Hynes Convention Center.
For more information on these events or to schedule a press briefing with Mr. Gittins, Dr. Gammel or Dr. Helums at the NSTI conference, please contact Derek Brookmeyer at 415-623-2076. For complete information about NSTI 2006, go to www.nsti.org.
About Advance Nanotech, Inc.
Advance Nanotech is dedicated to the successful commercialization of disruptive nanotechnologies to produce nano-enabled products. Advance provides financing and support services including commercialization guidance, project and infrastructure management, leadership assets, and counsel on intellectual property, licensing and regulatory issues to ensure maximum market potential. Advance Nanotech's diversified portfolio of 26 nanotechnologies, of which the company holds a majority stake in 21, impacts a range of applications including, but not limited to, sensors, medical therapeutics and composites. Advance is forging partnerships with leading manufacturers and universities in Europe, Asia and North America to transform innovative nanotechnology concepts into practical solutions. For more information on Advance Nanotech, please visit www.advancenanotech.com.
This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements.
Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech 's dependence on third parties and partners; and those risks described Advance Nanotech 's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements.
Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.